ArticleCell research2020
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Open access · hybridAbstract readClinical Trial, Phase I
In one paragraph
Article in Cell research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 424 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
424citing papers in PubMed, 1 pooled it
30.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
424 citing papers in PubMed, 1 synthesis or guideline pooled it, 951 citations in OpenAlex.
- Recent advances in application of hydrogel-based nanomaterials in breast cancer: from drug delivery, immunotherapy mechanisms to clinical applications.Journal of nanobiotechnology · 2026Pooled it
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Metal-phenolic nanocapsules enable a self-amplifying cuproptosis-STING cascade for synergistic cancer immunotherapy.Bioactive materials · 2026Article
- Targeted PD-L1 degradation with an injectable hydrogel reverses chemotherapy-induced compensatory immunosuppression and enhances antitumor immunity.Materials today. Bio · 2026Article
- Engineered mesenchymal stem cell-derived extracellular vesicles overexpressing miR-146a alleviate neuroinflammation in Alzheimer's disease.Neural regeneration research · 2026Article
- From mitochondria to innate immunity: The mtDNA-driven cGAS/STING-NLRP3 cascade and its therapeutic implications in neurodegenerative diseases (Review).Experimental and therapeutic medicine · 2026Review
- A tumor microenvironment-responsive calcium overload nanoplatform inducing PANoptosis for enhanced cancer immunotherapy.Materials today. Bio · 2026Article
- The cGAS-STING/MITA pathway in innate antiviral immunity and beyond.Cell insight · 2026Review
- AgBiSMaterials today. Bio · 2026Article
- GSH-responsive nanovaccine triggers immunogenic cell death and potent memory T cell immunity for durable, recurrence-free tumor eradication.Bioactive materials · 2026Article
- The cGAS-STING pathway: mechanistic basis, dual biological functions and translational therapeutic advances.Apoptosis : an international journal on programmed cell death · 2026Review
- Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Boron-embedded multifunctional nanoplatform toward potential combined boron neutron capture therapy and immunomodulation in glioma.Smart molecules : open access · 2026Article
- Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Manganese Ion-Based NanoPlatforms for Tumor Theranostics.Advanced healthcare materials · 2026Review
- Cold and hot tumors: immunological determinants, cancer-immunity cycle dysregulation, and nanotechnology-driven therapeutic approaches.Molecular biomedicine · 2026Review
- Spatial ecotype in tumor immune exclusion: from spatial architecture to therapeutic strategies.Molecular cancer · 2026Review
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
- Nanocarrier-based delivery of Pt(IV) compounds for chemoimmunotherapy and theranostics: Advances, challenges, and prospects.Acta pharmaceutica Sinica. B · 2026Review
- An MRI-visible nanotheranostic establishes a self-amplifying pyroptosis-STING-IFN-β circuit for CD8Materials today. Bio · 2026Article
364 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 2 countries.
Mengze Lv *Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.ORCID http://orcid.org/0000-0002-8509-7969
Meixia Chen *Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Rui ZhangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.
Wen ZhangInstitute for Immunology, Peking-Tsinghua Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China.
Chenguang WangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.
Yan ZhangDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Xiaoming WeiKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.
Yukun GuanKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.ORCID http://orcid.org/0000-0001-9312-0164
Jiejie LiuDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Kaichao FengDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Miao JingKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.
Xurui WangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.
Yun-Cai LiuInstitute for Immunology, Peking-Tsinghua Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China.
Qian MeiDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. meiqnn@hotmail.com.
Weidong HanDepartment of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China. hanwdrsw69@yahoo.com.ORCID http://orcid.org/0000-0003-3207-3899
Zhengfan JiangKey Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China. jiangzf@pku.edu.cn.ORCID http://orcid.org/0000-0002-1247-1382
Peking University · CNChinese PLA General Hospital · CNCenter for Life Sciences · CNCornell University · USNational Institutes of Health · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD8
Indexed as
ImmunotherapyAdjuvants, PharmaceuticAdultAgedAnimalsAntigen PresentationCarcinogenesisCD8-Positive T-LymphocytesCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDendritic CellsDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleHumansImmunityInterferon Type IAdjuvants, PharmaceuticcGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseInterferon Type IManganeseMembrane ProteinsNucleotidyltransferasesSting1 protein, mouseSTING Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.